Oritavancin

Summary

Oritavancin is a prescription‑only lipoglycopeptide antibiotic administered intravenously. It is approved for the treatment of serious Gram‑positive infections and is being explored for conditions such as bone and joint infections, infective endocarditis, and persistent adenotonsillar disease where bacterial biofilms play a role.

Mechanism of Action

As a member of the lipoglycopeptide class, oritavancin binds to the D‑Ala‑D‑Ala termini of peptidoglycan precursors, inhibiting cell‑wall transglycosylation and transpeptidation. In addition, its lipophilic side chain disrupts bacterial membrane integrity, providing rapid bactericidal activity against a broad range of Gram‑positive organisms, including MRSA.

What the Research Shows

A 2012 review of adenotonsillar disease highlighted oritavancin as an intracellularly active agent capable of reaching bacteria within biofilms. A 2019 pharmacokinetic review reported that oritavancin achieves bone and joint concentrations that exceed MIC90 values for common pathogens, suggesting utility in osteomyelitis and septic arthritis. A 2023 discussion of enterococcal endocarditis noted oritavancin among long‑acting lipoglycopeptides considered for outpatient parenteral therapy. Finally, a 2025 narrative review on therapeutic drug monitoring (TDM) included oritavancin as a newer anti‑MRSA drug, emphasizing its tissue penetration, dosing optimization, and toxicity monitoring. Across these sources, evidence is largely from reviews and pharmacokinetic assessments rather than large clinical trials.

Reported Benefits

The drug shows potent activity against resistant Gram‑positive bacteria, including MRSA and enterococci. Its pharmacokinetic profile provides high bone and joint tissue penetration and a long half‑life that enables infrequent dosing, facilitating outpatient treatment. Intracellular activity may help eradicate bacteria protected within biofilms, a feature noted in adenotonsillar disease contexts.

Limitations of the Evidence

Most data come from review articles and pharmacokinetic studies; robust clinical trial evidence for many of the discussed indications (bone infection, endocarditis, biofilm‑related disease) is limited or absent. The need for therapeutic drug monitoring indicates variability in exposure and a lack of standardized dosing regimens for some infections.

Safety Considerations

While specific adverse‑event rates are not detailed in the cited literature, the 2025 TDM review underscores toxicity as a consideration when using oritavancin, implying that monitoring for renal, hepatic, or infusion‑related reactions may be prudent. Clinicians are advised to apply therapeutic drug monitoring to balance efficacy with potential side effects.

How It Is Administered

Oritavancin is supplied for intravenous infusion only. Its formulation is designed for a single or limited number of doses due to a prolonged half‑life, allowing outpatient administration after initial hospital dosing.

Routes of Administration

Goals & Uses

• Single-dose outpatient antibiotic therapyHealthcare UtilizationHigh
• Treatment of ABSSSIInfectious DiseaseHigh
• Treatment of MRSA infectionsAntimicrobialHigh
• Treatment of VRE infectionsAntibacterial TherapyLow
• Coverage of MRSA and VREAntimicrobial SpectrumHigh
• Treatment of ABSSSI due to gram-positive pathogensAntibacterial TherapyHigh

Contraindications

• Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
• Unfractionated heparin sodium use within 120 hoursDrug InteractionHigh
• Hypersensitivity to oritavancin or other glycopeptidesAllergyHigh
• Known hypersensitivity to oritavancin or glycopeptidesAllergyHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• OsteomyelitisMusculoskeletalUncommon
• Infusion-related reactions (flushing, pruritus, urticaria)Infusion ReactionCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Infusion‑related reactions (flushing, pruritus, rash)LocalCommon
• Nausea/vomitingGastrointestinalCommon
• Clostridium difficile-associated diarrheaGastrointestinalRare
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

• Other anticoagulants (e.g., direct oral anticoagulants)Low
• CYP2C9/CYP2C19 substrates (e.g., phenytoin, warfarin)Low
• WarfarinModerate
• Unfractionated HeparinHigh

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairment (severe)HepaticRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patients (<18 years)AgeRelative
• Pediatric patients (<18 y)AgeRelative
• Pregnancy and lactationReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Acute bacterial skin and skin‑structure infectionsMarketing authorization granted 2015; same dosing schedule.
• United StatesApprovedApproved: Acute bacterial skin and skin‑structure infectionsApproved 2014; single‑dose IV regimen.
• United KingdomApprovedApproved: Acute bacterial skin and skin structure infections (ABSSSI) in adultsApproved by MHRA; indications consistent with EU approval.

FDA‑approved in 2014 (Orbactiv) for ABSSSI; later approved in the EU for the same indication. Not recommended for routine use in pregnancy or pediatric patients without specific data.

Evidence & Sources

• Adenotonsillar disease
  Journal ArticleModerateZautner AE2012-01-01T00:00:00.000000Z
• Antibiotic penetration into bone and joints: An updated review
  Journal ArticleModerateThabit AK, et al.2019-01-01T00:00:00.000000Z
• Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
  Journal ArticleModerateHerrera-Hidalgo L, et al.2023-01-01T00:00:00.000000Z
• Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians
  Journal ArticleModerateGalfo V, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions